Figures
- Figure 1–
Study design. PAH: pulmonary arterial hypertension.
- Figure 2–
a) 3-yr survival of the entire cohort of 674 pulmonary arterial hypertension (PAH) patients. b) 3-yr survival in PAH patients with congenital heart disease (CHD; ——), idiopathic PAH (……) or connective tissue disease (CTD; ------); p<0.05.
- Figure 3–
a) 3-yr survival of the entire cohort of 674 pulmonary arterial hypertension (PAH) patients, according to sex. —: females; ---: males. p<0.001. b) 3-yr survival of the entire cohort of 674 PAH patients, according to age at study entry. ——: ≤51 yrs; ------: >51 yrs. p<0.001 c) 3-yr survival of the entire cohort of 674 PAH patients, according to New York Heart Association functional class (FC) at study entry. ——: FC I/II; ……: FC III; ------: FC IV. p<0.001.
- Figure 4–
a) 3-yr survival from study entry of incident (------) and prevalent (——) patients with idiopathic, familial and anorexigen-associated pulmonary arterial hypertension. b) Survival from study entry according to quartiles of time from diagnosis in the prevalent population. ——: >80 months; ……: 40–80 months; ------: 16–40 months; – – – –: <16 months. p<0.001.
